Agios Pharma (NASDAQ:AGIO) Covered By Yet Another Research Firm

May 24, 2018 - By Dolores Ford

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Investors sentiment increased to 1.22 in Q4 2017. Its up 0.01, from 1.21 in 2017Q3. It improved, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported.

Invesco reported 0.02% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Art Advisors Ltd holds 0.07% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 26,335 shares. Bessemer Grp accumulated 107 shares. Moreover, Columbia Wanger Asset Mngmt Lc has 0.65% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Us Bankshares De stated it has 113 shares. Moreover, Sei Invs has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 2,869 shares. 33,978 were reported by Credit Suisse Ag. Fmr Lc has invested 0.05% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Moreover, Alkeon Cap Management Ltd Liability has 0.17% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 511,619 shares. Principal Fincl Gp reported 0% stake. 14,600 are held by Spark Inv Ltd Liability Company. holds 2.81 million shares. Capital Guardian reported 0.54% stake. Hood River Limited Liability Com owns 130,617 shares for 0.43% of their portfolio. Bnp Paribas Arbitrage has invested 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Since January 10, 2018, it had 1 insider purchase, and 23 selling transactions for $18.55 million activity. Biller Scott also sold $228,128 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. Shares for $1.01M were sold by Schenkein David P on Monday, April 2. Alenson Carman sold $161,250 worth of stock. 2,050 shares valued at $176,198 were sold by Hoerter Steven L. on Monday, April 23. $557,396 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Foster-Cheek Kaye I. 200 shares valued at $16,688 were bought by Scadden David on Friday, March 16.

Why Has Citigroup Given Agios Pharma (NASDAQ:AGIO) a $117.0000 Price Target

Citigroup has just issued a “Buy” rating for Agios Pharma (NASDAQ:AGIO) shares. The firm has begun coverage on shares of AGIO in an analyst report issued to clients on Wednesday, 23 May. This target price per share suggests upside of 31.56 % from the previous stock close of Agios Pharma (NASDAQ:AGIO).

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 4 analysts covering Agios Pharma (NASDAQ:AGIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Agios Pharma has $95 highest and $80.0 lowest target. $89.33’s average target is 0.45% above currents $88.93 stock price. Agios Pharma had 5 analyst reports since February 14, 2018 according to SRatingsIntel. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Wednesday, February 14 by RBC Capital Markets. As per Wednesday, April 11, the company rating was maintained by Credit Suisse. Credit Suisse maintained the shares of AGIO in report on Thursday, February 15 with “Buy” rating. On Thursday, February 15 the stock rating was maintained by JP Morgan with “Overweight”.

The stock increased 3.48% or $2.99 during the last trading session, reaching $88.93. About 600,449 shares traded or 62.46% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since May 24, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on August, 14. They expect $-1.66 EPS, up 6.74 % or $0.12 from last year’s $-1.78 per share. After $-1.63 actual EPS reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.84 % negative EPS growth.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.12 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Seekingalpha.com which released: “A Fresh Look At Celgene After Q1 And New Info On Ozanimod” on May 08, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” published on April 29, 2018, Nasdaq.com published: “Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results …” on April 27, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Seekingalpha.com and their article: “Agios Pharmaceuticals (AGIO) Investor Presentation – Slideshow” published on May 04, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 23, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.